NICE tackles "major challenge" of radical colorectal cancer therapy costs
This article was originally published in Clinica
The early diagnosis of suspicious symptoms, variations in care policy and the "major economics challenge" posed by radical therapies are among the issues that the UK's National Institute for Health and Clinical Excellence (NICE) will focus on to develop a clinical practice guideline for colorectal cancer. Its proposed scope is now out for consultation, until March 18.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.